Last reviewed · How we verify
Pemetrexed Disodium Injection — Competitive Intelligence Brief
phase 3
Antifolate antimetabolite
Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Pemetrexed Disodium Injection (Pemetrexed Disodium Injection) — Shanghai Miracogen Inc.. Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pemetrexed Disodium Injection TARGET | Pemetrexed Disodium Injection | Shanghai Miracogen Inc. | phase 3 | Antifolate antimetabolite | Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase | |
| Pemetrexed + oral folinic acid rescue | Pemetrexed + oral folinic acid rescue | Radboud University Medical Center | marketed | Antifolate antimetabolite | Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase | |
| Intrathecal injection of pemetrexed | Intrathecal injection of pemetrexed | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | marketed | Antifolate antimetabolite | Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase | |
| Pemetrexed + cisplatin | Pemetrexed + cisplatin | AstraZeneca | phase 3 | Antifolate antimetabolite + platinum-based alkylating agent | Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (cisplatin) | |
| Pemetrexed + Cisplatin /Carboplatin | Pemetrexed + Cisplatin /Carboplatin | Jiangsu Hansoh Pharmaceutical Co., Ltd. | phase 3 | Antineoplastic agent | Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase | |
| Pemetrexed + carboplatin | Pemetrexed + carboplatin | AstraZeneca | phase 3 | Antifolate antimetabolite + platinum-based chemotherapy combination | Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (carboplatin) | |
| nedaplatin+pemetrexed | nedaplatin+pemetrexed | Sun Yat-sen University | phase 3 | Platinum-based chemotherapy, Antifolate | DNA, Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antifolate antimetabolite class)
- Allist Pharmaceuticals, Inc. · 1 drug in this class
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
- Mundipharma K.K. · 1 drug in this class
- Radboud University Medical Center · 1 drug in this class
- Shanghai Miracogen Inc. · 1 drug in this class
- The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pemetrexed Disodium Injection CI watch — RSS
- Pemetrexed Disodium Injection CI watch — Atom
- Pemetrexed Disodium Injection CI watch — JSON
- Pemetrexed Disodium Injection alone — RSS
- Whole Antifolate antimetabolite class — RSS
Cite this brief
Drug Landscape (2026). Pemetrexed Disodium Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-disodium-injection. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing